Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Roche

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

The Conversation

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How science is getting closer to a world without animal testing

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Financial Times

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga Before The Bell: Baidu Beats Tesla, Finland Sells $47.5M Bitcoins, Tesla's Bitcoin Sale And Other Top Financial Stories Thursday, July 21

CNBC

Benzinga

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

StockNews.com

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients

Roche Holdings AG (OTC:RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease. Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function. The…

Benzinga

AstraZeneca boss 'wouldn't change a thing' despite Covid vaccine 'setbacks'

Jab saved one million lives, says Sir Pascal Soriot

Wales Online

Test makers target monkeypox market as cases surge

Diagnostic companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments ramp up efforts to trace the world's first major outbreak of the viral infection outside of Africa.

Reuters

New sight loss drug made available to thousands on the NHS

Data suggests some patients can now wait up to 16 weeks between doses.

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Asharq Al-Awsat

Cancer Coalition Aims to Boost Access to Medicines in Poorer Countries

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries,…

Bangkok Post

Post-pandemic healthcare

Health crises and emergencies such as Covid-19 have brought into sharp focus the critical need for preparedness. The unprecedented pandemic has led to a dynamically changing environment across the healthcare industry, posing challenges that call for innovative solutions.

Asharq Al-Awsat

Blow to Roche’s Cancer Immunotherapy Prospects as 2nd Trial Fails

Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial. In a study, a combination of tiragolumab and Roche's established Tecentriq drug did not reduce the rate of disease…

Benzinga

Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials

The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Tribune News Service

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Benzinga

AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

Benzinga

FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults

The FDA has granted priority review to Roche Holdings AG's (OTC:RHHBY) Actemra/RoActemra (tocilizumab) for COVID-19 in hospitalized adults. "If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for treating COVID-19 in hospitalized patients," Roche said. The Compay also added that more than 1 million people hospitalized with COVID-19 had been treated with Actemra/RoActemra…

Benzinga

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

Here's a roundup of top developments in the biotech space over the last 24 hours.

Asharq Al-Awsat

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

Benzinga

Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population

At the annual congress of the Muscular Dystrophy Association (MDA), Roche Holdings AG (OTC:RHHBY) announced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is a novel survival motor neuron 2 (SMN2) splicing modifier, licensed from PTC Therapeutics Inc (NASDAQ:PTCT). At the annual MDA event, Roche’s presentations included new three-year data from the…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.